Specialised Products
K-Beauty Products
Bringing Korean beauty products into the EU and UK. Korean MFDS compliance does not transfer, and the ingredient and UV-filter gaps are where most K-beauty launches stumble.
K-beauty has reshaped the market with multi-step routines, sheet masks, essences and inventive formats. The regulatory point that catches importers out is simple: a product fully compliant in South Korea is not, on that basis, compliant in the EU or UK.
Korean approval does not transfer
A product cleared under the Korean Cosmetics Act and the MFDS still needs a full Cosmetic Product Safety Report, an EU or UK Responsible Person, and notification through the CPNP or the SCPN before it can be sold here. None of the Korean documentation substitutes for that.
Ingredient and filter gaps
The substantive risk is composition. Korea permits UV filters and certain ingredients that do not appear on the EU and UK positive lists, Annex VI for filters in particular, so a popular Korean sunscreen can be unlawful here without reformulation. Novel ingredients and fermentation-derived materials need checking against the European inventories, and Korean claims need re-assessing against Regulation (EU) No 655/2013. We map the formulation against the EU and UK requirements, identify the gaps, and prepare the assessment and notification.
Relevant services
CPSR
From £70 · 2 to 3 days
The Cosmetic Product Safety Report is the safety assessment required under Article 10 and Annex I of Regulation (EC) No 1223/2009 before a cosmetic product may be placed on the UK or EU market. Prepared and signed by a qualified safety assessor.
Learn more →Responsible Person
From £149 · per product, per year
Oxford Biosciences acts as your Responsible Person in the UK and the EU under a single quality management system, holding the regulatory obligation: PIF maintenance, SCPN and CPNP notification, labelling oversight, and cosmetovigilance.
Learn more →Global Markets
From £149
Cosmetic regulatory documentation for markets beyond the EU and UK: Canada, Australia, New Zealand, ASEAN, the GCC and Latin America, prepared from the same evidence base by the assessor who signs our CPSRs.
Learn more →Frequently asked questions
What is a CPSR?
A Cosmetic Product Safety Report (CPSR) is the safety assessment required by Article 10 and Annex I of Regulation (EC) No 1223/2009 before a cosmetic product is placed on the UK or EU market. Annex I sets out two parts: Part A, the cosmetic product safety information (composition, physico-chemical and microbiological characteristics, stability, exposure and the toxicological profile of each substance), and Part B, the safety assessment, in which a qualified assessor states and reasons the conclusion on safety. It is the pivotal scientific document held within the Product Information File.
What is a Responsible Person?
Every cosmetic product placed on the EU or UK market must have a Responsible Person established within that jurisdiction. Under Articles 4 and 5 of Regulation (EC) No 1223/2009, the Responsible Person is the legal entity that holds the regulatory obligation for the product: it maintains the Product Information File, makes the CPNP or SCPN notification, oversees labelling, and handles cosmetovigilance and contact with the competent authority. It is not simply a postal address. Oxford Biosciences acts as Responsible Person in both the UK and the EU under a single quality management system.
Which international markets does Oxford Biosciences cover?
Beyond the EU and UK, Oxford Biosciences prepares the United States MoCRA Toxicological Risk Assessment (£395), the Canadian Health Canada Cosmetic Notification (£395), the Australian AICIS Compliance Statement (£149), the New Zealand EPA Group Standard Compliance Statement (£179), and the ASEAN Cosmetic Directive Documentation Package (£249), with GCC and Latin American markets (Brazil, Mexico, Argentina and Chile) quoted on application. Where markets share an evidence base, a single Product Information File carries the jurisdiction-specific annexes rather than requiring a separate dossier for each.